Patients With IDH1 Positive Recurrent Grade II Glioma Enrolled in a Safety and Immunogenicity Study of Tumor-Specific Peptide Vaccine

Trial Profile

Patients With IDH1 Positive Recurrent Grade II Glioma Enrolled in a Safety and Immunogenicity Study of Tumor-Specific Peptide Vaccine

Recruiting
Phase of Trial: Phase I

Latest Information Update: 18 Jun 2017

At a glance

  • Drugs PEPIDH1M (Primary)
  • Indications Glioma
  • Focus Adverse reactions
  • Most Recent Events

    • 18 Jun 2017 Last checked against ClinicalTrials.gov record.
    • 10 Jun 2017 Biomarkers information updated
    • 10 Apr 2017 Planned primary completion date changed from 1 May 2017 to 1 Jun 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top